Today: 10 June 2026
AppLovin stock heads into Monday under a short-seller shadow as Fed week nears
25 January 2026
2 mins read

AppLovin stock heads into Monday under a short-seller shadow as Fed week nears

New York, January 25, 2026, 16:03 EST — The market has closed.

  • After a choppy session, AppLovin shares closed Friday a bit higher.
  • The company’s denial has done little to shake off the overhang created by short-seller allegations.
  • Investors are eyeing the Fed decision this week and AppLovin’s earnings report in February.

AppLovin shares (APP.O) start Monday weighed down by lingering short-seller pressure, having closed Friday at $524.41. The stock has dropped roughly 22% since Dec. 31 and fell another 0.7% in after-hours trading to $520.92.

The swings carry extra weight now that AppLovin is part of the S&P 500, triggering more activity from passive funds and index-linked flows. This inclusion also means the stock draws more attention whenever tech volatility picks up.

The Federal Reserve meets Jan. 27-28, kicking off a packed week of U.S. earnings that could shift views on high-multiple growth stocks. “At the end of the day, earnings are the driver,” said Franklin Templeton strategist Chris Galipeau in a Reuters report. Reuters

Trouble for AppLovin kicked off Tuesday when short-seller CapitalWatch released a report claiming ties to money laundering. The stock reacted swiftly, dropping up to 4.7% in premarket trading, per an story.

On Wednesday, AppLovin fired back at the report, labeling it “rife with false, misleading, and nonsensical allegations” in an emailed statement to Investing.com. The company went further, saying it “categorically reject[s]” the accusations and stressed it has no control over who buys, holds, or sells its shares. Investing.com

The short-seller assault also brought AppLovin’s data practices back into focus following an October Reuters report that the U.S. SEC was investigating the company’s data-collection methods, citing a Bloomberg News report and sources familiar with the situation. Reuters noted the regulator hadn’t accused AppLovin or its executives of any misconduct.

Certain analysts remain bullish on AppLovin, highlighting its role as a key player in mobile gaming advertising and its expanding e-commerce performance segment. Evercore ISI’s Robert Coolbrith kicked off coverage earlier this month with an Outperform rating and an $835 price target, dubbing AppLovin the “dominant” platform in mobile gaming ad tech, according to TheFly via TipRanks. TipRanks

Supporters highlight Axon, AppLovin’s AI-driven ad recommendation engine, and its result-based pricing model, such as “cost-per-action,” where advertisers pay only when a user takes a specific action, not just for ad impressions. Morningstar analyst Mark Giarelli noted in a Nasdaq.com report that Axon has outperformed Meta’s ad tools and other platforms in return on ad spend. The piece also drew a contrast between AppLovin’s method and that of competitors like The Trade Desk. Nasdaq

The broader market showed volatility as well. The Nasdaq edged up 0.28% on Friday, while the Dow dropped 0.58%. Intel’s earnings outlook hurt risk appetite, Reuters noted.

AppLovin is set to unveil its quarterly numbers soon, releasing fourth-quarter and full-year 2025 results after the U.S. market wraps up on Feb. 11. CEO Adam Foroughi and CFO Matthew Stumpf will host a 5 p.m. ET webinar to discuss the report.

Yet the stock’s recent rollercoaster ride proves how fast sentiment can shift. Fresh info linked to the short report, a regulatory update, or a cautious February outlook might slam the shares again.

Traders will be eyeing Monday’s open for signs of momentum. The next key milestones are the Fed’s decision on Wednesday and AppLovin’s earnings report on Feb. 11.

Stock Market Today

  • PureTech Health PLC Annual General Meeting Results June 2026
    June 10, 2026, 1:22 PM EDT. PureTech Health plc held its Annual General Meeting on June 10, 2026, approving all 15 shareholder resolutions. Key approvals included the Annual Report and Accounts for 2025, director re-elections, and auditor appointments with over 93% support across motions. Shareholders authorized share allotment and disapplication of pre-emption rights, essential for company capital management. The meeting saw strong backing for governance measures, including remuneration reports and market purchase authorizations. Total outstanding shares were 243.4 million, each carrying one vote, with comprehensive proxy participation detailed. Full resolutions are accessible via PureTech's website and the National Storage Mechanism. PureTech Health is a biotherapeutics company focused on innovative science-led healthcare solutions.

Latest articles

BigBear.ai Stock Bounces as Shareholder Vote Squeeze Meets Panama AI Speculation

BigBear.ai Stock Bounces as Shareholder Vote Squeeze Meets Panama AI Speculation

10 June 2026
BigBear.ai shares rose 2.8% to $4.10 as investors weighed the approved move to double authorized shares to 1 billion, giving the company flexibility for financing but raising dilution risks, while the Panama cargo-security rollout and $281.9 million backlog keep growth hopes alive amid ongoing losses and revenue conversion questions.
Cracker Barrel Jumps After Surprise Profit Forces Investors to Rethink Turnaround

Cracker Barrel Jumps After Surprise Profit Forces Investors to Rethink Turnaround

10 June 2026
Cracker Barrel shares soared 26% after a surprise Q3 profit and raised 2026 revenue and adjusted EBITDA outlook, even as restaurant traffic stayed negative; investors focused on improved guidance and cost cuts, with Wells Fargo upgrading the stock and raising its price target to $50, but risks remain if guest counts don’t recover.
Lemonade Shares Jump as Investors Zero In on Profit Path

Lemonade Shares Jump as Investors Zero In on Profit Path

10 June 2026
Lemonade shares jumped 10.6% to an intraday high above $60 after CEO Daniel Schreiber and CFO Tim Bixby appeared at Morgan Stanley’s U.S. Financials Conference, as investors focused on the company’s reiterated target for positive adjusted EBITDA in Q4 and a fresh TD Cowen price target hike, with shrinking losses and improved underwriting driving optimism.
Nestle stock faces Monday test after France probes baby deaths tied to recalled formula
Previous Story

Nestle stock faces Monday test after France probes baby deaths tied to recalled formula

Zhongji Innolight (300308.SZ) stock: China’s new fund-favorite faces a Monday test after a 5.8% slide
Next Story

Zhongji Innolight (300308.SZ) stock: China’s new fund-favorite faces a Monday test after a 5.8% slide

Go toTop